Vir Scores In Oncology Pivot With Strong Early T-Cell Engager Results

Five months after taking over the dual-masked T-cell engagers from Sanofi amid a restructuring, the company posted promising initial Phase I data from its PSMA- and HER2-targeting IO candidates.